Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases

[1]  B. Andersson,et al.  Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation , 2021, Bone Marrow Transplantation.

[2]  D. Steensma,et al.  Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. , 2020, Blood reviews.

[3]  M. Doğu,et al.  Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts , 2020, Journal of hematology.

[4]  H. Kantarjian,et al.  CPX-351 (vyxeos) in AML , 2019, Leukemia & lymphoma.

[5]  Peter A. Jones,et al.  A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. , 2018, Blood.

[6]  M. Lübbert,et al.  DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. , 2017, Seminars in cancer biology.

[7]  J. Klco,et al.  The genomic landscape of pediatric myelodysplastic syndromes , 2016, Nature Communications.

[8]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  C. Tirado,et al.  Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review , 2014, Experimental Hematology & Oncology.

[11]  D. Johnston,et al.  Outcome of pediatric patients with acute myeloid leukemia (AML) and −5/5q− abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group , 2013, Pediatric blood & cancer.

[12]  R. Garzon,et al.  Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults , 2013, British journal of haematology.

[13]  K. Manola.  Cytogenetics of pediatric acute myeloid leukemia , 2009, European journal of haematology.

[14]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[15]  Michael F Clarke,et al.  Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation , 2007, Nature Medicine.

[16]  Y. Hayashi,et al.  Therapy-related myelodysplastic syndrome in childhood: a retrospective study of 36 patients in Japan. , 2005, Leukemia research.